Geneva, April 20 -- International Clinical Trials Registry received information related to the study (KCT0011834) titled 'An investigator-initiated clinical trial to evaluate the safety and efficacy of methotrexate and rituximab in patients with rapidly destructive periodontitis' on April 10.
Study Type: Interventional Study
Study Design:
Primary Purpose : Treatment, Intervention Model : Parallel, Blinding/Masking : Open, Allocation : RCT
Primary Sponsor: Yonsei University Health System, Dental Hospital
Condition:
Diseases of the digestive system
Intervention:
Drug : In the methotrexate group, MTX will be administered orally once weekly, starting at 7.5 mg/week. After safety evaluation (including adverse events, vital signs, phys...